Beacon Therapeutics

Beacon Therapeutics is a clinical-stage biotechnology company focused on developing gene therapies to save and restore sight for people with blinding retinal diseases. Its work spans rare and prevalent ocular conditions, including X-linked retinitis pigmentosa (XLRP), dry age-related macular degeneration (dAMD), and cone-rod dystrophy (CRD). The company uses adeno-associated virus (AAV) gene therapy, an approach that adds a functional copy of a mutated gene so a patient’s cells can produce proteins intended to treat or prevent genetic conditions. Beacon says a single treatment may offer long-lasting benefits and improve quality of life.

The company’s activities include scientific research, clinical trials, and the development of product candidates; it does not describe a marketed treatment in the supplied information. Its clinical work includes laru-zova for XLRP, with the company reporting ongoing, encouraging trial results. Beacon also shares information about its science, disease areas, publications, and clinical trials, and invites professionals interested in its mission to explore career opportunities.